Millennials among those most vulnerable; show a 101% higher risk of depression than middle-aged counterparts.
SAN FRANCISCO and WASHINGTON, August 20, 2020 – The risk for depression among US workers has risen an alarming 102% since February, according to findings from the Mental Health Index. The escalating threat of developing depressive mood disorder shows little sign of abating. Between June and July, the risk of depression climbed a staggering 31%.
The Mental Health Index: U.S. Worker Edition, powered by Total Brain, a leading mental health and brain performance self-monitoring and self-care platform, is distributed in partnership with the National Alliance of Healthcare Purchaser Coalitions, One Mind at Work, and the newest coalition members, the HR Policy Association and its American Health Policy Institute.
Additional findings from Total Brain’s clinically-validated brain assessments show millennials are among the most emotionally vulnerable groups in the COVID-19 era. Working Americans ages 20-39 have a:
These findings come on the heels of new CDC data revealing one in four young adults say they have considered suicide in the past month because of the coronavirus.
“It has been more than five months since the WHO declared COVID-19 a pandemic,” noted Louis Gagnon, CEO, Total Brain. “People are experiencing sustained elevation in stress and anxiety levels like never before. The fact that the risk of developing clinical depression continues to escalate at such a disturbing rate comes as little surprise. Depression is the manifestation of months of chronic stress and anxiety overload.”
AI in Health Care: Balancing Governance, Innovation, and Trust
September 2nd 2025In this conversation with Reuben Daniel, associate vice president of artificial intelligence at UPMC Health Plan, we dive into how UPMC Health Plan builds trust with providers and members, discuss challenges of scaling AI effectively, and hear about concrete examples of AI's positive impact.
Listen
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More